Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofrogliptin versus acarbose in drug-naïve type 2 diabetes
NCT07122102Not yet recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cofrogliptin in type 2 diabetes mellitus (T2DM), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Glycated hemoglobin at 12 weeks. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07122102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122102.